CRISPR Therapeutics AG (CRSP) Change in Cash (2015 - 2026)

CRISPR Therapeutics AG (CRSP) has 12 years of Change in Cash data on file, last reported at $72.2 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Cash rose 214.53% year-over-year to $72.2 million; the trailing twelve-month figure through Mar 2026 stood at $184.6 million (up 139.09% YoY), and the FY2025 full-year result was $49.3 million, up 154.0% from the prior year.
• Change in Cash advanced to $72.2 million in Q1 2026, from $61.1 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $317.9 million in Q1 2024 to a low of -$286.3 million in Q4 2022.
• A 5-year average of -$29.9 million and a median of -$2.7 million in 2022 frame the typical range for Change in Cash.
• Across the five-year window, Change in Cash plunged 461.8% in 2022 and surged 3126.99% in 2023, its largest moves.
• Tracing CRSP's Change in Cash over 5 years: stood at -$286.3 million in 2022, then soared by 51.61% to -$138.5 million in 2023, then surged by 152.4% to $72.6 million in 2024, then slipped by 15.88% to $61.1 million in 2025, then gained by 18.3% to $72.2 million in 2026.
• Business Quant data shows CRSP's Change in Cash at $72.2 million in Q1 2026, $61.1 million in Q4 2025, and $92.9 million in Q3 2025.